MX2020003211A - Proteina de fusion que comprende una porcion de fgf-18. - Google Patents

Proteina de fusion que comprende una porcion de fgf-18.

Info

Publication number
MX2020003211A
MX2020003211A MX2020003211A MX2020003211A MX2020003211A MX 2020003211 A MX2020003211 A MX 2020003211A MX 2020003211 A MX2020003211 A MX 2020003211A MX 2020003211 A MX2020003211 A MX 2020003211A MX 2020003211 A MX2020003211 A MX 2020003211A
Authority
MX
Mexico
Prior art keywords
moiety
fgf
fusion protein
cartilage
osteoarthritis
Prior art date
Application number
MX2020003211A
Other languages
English (en)
Inventor
Anne Gigout
Christian Brenneis
Thomas Rysiok
Stefan Zielonka
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2020003211A publication Critical patent/MX2020003211A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a nuevas proteínas de fusión que comprenden una porción de FGF-18 fusionada a una porción anti-NGF. Dicha proteína de fusión puede ser utilizada para el tratamiento del desorden de un cartílago tal como osteoartritis o daño al cartílago.
MX2020003211A 2017-09-21 2018-09-20 Proteina de fusion que comprende una porcion de fgf-18. MX2020003211A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17192467 2017-09-21
EP18182696 2018-07-10
PCT/EP2018/075432 WO2019057805A1 (en) 2017-09-21 2018-09-20 FUSION PROTEIN COMPRISING A FRACTION FGF-18

Publications (1)

Publication Number Publication Date
MX2020003211A true MX2020003211A (es) 2020-09-21

Family

ID=63557503

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003211A MX2020003211A (es) 2017-09-21 2018-09-20 Proteina de fusion que comprende una porcion de fgf-18.

Country Status (15)

Country Link
US (1) US11572395B2 (es)
EP (1) EP3684791A1 (es)
JP (1) JP7237945B2 (es)
KR (1) KR20200054300A (es)
CN (1) CN111132997A (es)
AU (1) AU2018337686B2 (es)
BR (1) BR112020005035A2 (es)
CA (1) CA3074483A1 (es)
CL (1) CL2020000733A1 (es)
IL (1) IL273271A (es)
MX (1) MX2020003211A (es)
PH (1) PH12020550099A1 (es)
RU (1) RU2020113713A (es)
SG (1) SG11202001772SA (es)
WO (1) WO2019057805A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3511340B1 (en) 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
KR20210080460A (ko) * 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
CN113151185B (zh) * 2020-11-17 2023-06-23 苏州仁端生物医药科技有限公司 分泌抗fgf18单克隆抗体杂交瘤细胞株及其单抗、应用
EP4384218A4 (en) * 2021-08-09 2025-11-05 Merck Patent Gmbh Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines
CN117721115A (zh) * 2022-09-06 2024-03-19 深圳瑞吉生物科技有限公司 用于治疗骨关节炎的mRNA及其制备方法与应用
JP2026520908A (ja) * 2023-06-05 2026-06-25 ピュア バイオロジクス スプウカ アクツィイナ 抗ｇａｒｐ抗体及び使用方法
CN120058930B (zh) * 2025-02-27 2026-05-29 中国医学科学院基础医学研究所 一种靶向神经营养因子BDNF和NGF的IgA抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75316C2 (uk) 1996-10-16 2006-04-17 Займодженетікс, Інк. Гомологи з фактором росту фібробласта
US7470665B2 (en) * 1999-12-02 2008-12-30 Zymogenetics, Inc. Methods for targeting cells that express fibroblast growth receptor-3 or -2
US6855510B2 (en) * 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
EP1551426B1 (en) 2002-10-07 2014-06-25 ZymoGenetics, Inc. Methods of administering fgf18
US20050202043A1 (en) * 2004-02-23 2005-09-15 Borean Pharma A/S Multimerised HIV fusion inhibitors
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
US8207115B2 (en) * 2006-08-25 2012-06-26 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
CN101993485B (zh) * 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
ES2665954T3 (es) * 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
CA2938066C (en) 2014-02-02 2025-05-06 Medimmune Limited CHIMERIC PROTEIN COMPOSED OF NERVE GROWTH FACTOR ANTAGONIST DOMAIN AND TUMOR NECROSIS FACTOR-ANTAGONIST DOMAIN-A
ES2935274T3 (es) * 2014-12-05 2023-03-03 Merck Patent Gmbh Anticuerpo con intercambio de dominios
CA2994638A1 (en) 2015-08-13 2017-02-16 Merck Patent Gmbh Combination composition comprising fgf-18 compound

Also Published As

Publication number Publication date
SG11202001772SA (en) 2020-04-29
JP7237945B2 (ja) 2023-03-13
IL273271A (en) 2020-04-30
US20200299347A1 (en) 2020-09-24
AU2018337686B2 (en) 2023-04-20
KR20200054300A (ko) 2020-05-19
RU2020113713A3 (es) 2022-03-03
RU2020113713A (ru) 2021-10-21
AU2018337686A1 (en) 2020-03-19
PH12020550099A1 (en) 2020-09-14
US11572395B2 (en) 2023-02-07
CA3074483A1 (en) 2019-03-28
CN111132997A (zh) 2020-05-08
BR112020005035A2 (pt) 2020-09-15
WO2019057805A1 (en) 2019-03-28
CL2020000733A1 (es) 2020-10-02
EP3684791A1 (en) 2020-07-29
JP2020536511A (ja) 2020-12-17

Similar Documents

Publication Publication Date Title
PH12020550099A1 (en) Fusion protein comprising an fgf-18 moiety
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
GEAP202114720A (en) Constructs having a sirp-alpha domain or variant thereof
EA201890423A1 (ru) Слитые белки фактора ix, способы их получения и применения
PH12018500694A1 (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
EA201691576A1 (ru) Слитые белки, содержащие интерлейкин-2, и их применения
PH12018502361B1 (en) Gdf15 fusion proteins and uses thereof
PH12016501441B1 (en) Chimeric alkaline phosphatase-like proteins
ZA201805721B (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
EP3313426A4 (en) FUSION PROTEINS FOR INHIBITING THE ANGIOGENESIS
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EP3543335A3 (en) Soluble intein fusion proteins and methods for purifying biomolecules
HUP1500363A2 (en) Method for increasing the galactose content of recombinant proteins
IL254242A0 (en) Dual signaling fusion proteins and methods of using them to treat diseases
EA201890434A1 (ru) Антитела к cd154 и способы их применения
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
ZA201801498B (en) An improved refolding process for antibody's fragments
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EP3697428A4 (en) ARTIFICIAL SECRETION PEPTIDES FOR THE PRODUCTION OF HETEROLOGICAL PROTEINS
MX2017003729A (es) Peptidos a base de estaterina.
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
MA45227A (fr) Peptides pour le traitement de l'ostéoarthrite
IL249610A (en) Chimeric proteins for cancer treatment
MX2018001816A (es) Composicion combinada que comprende el compuesto fgf-18.